聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 12 分钟 23 秒 前

Genkyotex Announces New Senior Management and Board Appointments

周一, 05/19/2014 - 11:50
GENEVA & ARCHAMPS, France--(Healthcare Sales & Marketing Network)--Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the appointment of Dr. Jeanette Wood as Chief Scientific Officer and Dr. Joseph McCracken to the Board o...
Biopharmaceuticals, Personnel
Genkyotex, GKT137831, NOX inhibitors

Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults

周一, 05/19/2014 - 11:45
FDA submission planned for 1st Quarter 2015 Shire forms business unit focused in ophthalmics LEXINGTON, Massachusetts, May 19, 2014 -- (Healthcare Sales & Marketing Network) -- Following a May 15, 2014, meeting with the U.S. Food and Drug Administra...
Biopharmaceuticals, Ophthalmology
Shire plc, dry eye disease, Lifitegrast

OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer

周五, 05/16/2014 - 14:26
SOUTH SAN FRANCISCO, Calif., May 16, 2014 -- (Healthcare Sales & Marketing Network) -- OXiGENE, Inc. (OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David (Dai) Chaplin, Ph.D., has been appoi...
Biopharmaceuticals, Oncology, Personnel
OXiGENE, vascular disrupting agents

Proteon Therapeutics Announces $45 Million of Series D Financing

周五, 05/16/2014 - 14:24
Company Poised to Initiate Phase 3 Trial of PRT-201 for Reduction of AVF Failure in Hemodialysis WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--Proteon Therapeutics Inc., a privately held biopharmaceutical company developing novel, first-in-cla...
Biopharmaceuticals, Venture Capital
Proteon Therapeutics, Elastase, hemodialysis, vascular access

Sorbent Therapeutics Closes First Tranche Of $15 Million Series D Financing

周四, 05/15/2014 - 15:05
Completes Enrollment in Phase 2b Clinical Trial of CLP-1001 for Heart Failure SUNNYVALE, Calif., May 15, 2014 -- (Healthcare Sales & Marketing Network) -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular a...
Biopharmaceuticals, Cardiology, Venture Capital
Sorbent Therapeutics, Heart Failure

Boston Scientific Announces Definitive Agreement To Acquire Interventional Division Of Bayer AG

周四, 05/15/2014 - 15:01
Acquisition Expected to Strengthen Peripheral Interventions Business and Accelerate Growth in Peripheral Atherectomy and Thrombectomy Categories NATICK, Mass., May 15, 2014 -- (Healthcare Sales & Marketing Network) -- In a move to expand significantly ...
Devices, Interventional, Acquisitions
Boston Scientific, Bayer AG, Bayer Interventional, AngioJet, Thrombectomy

TERUMO(R) Launches Expanded GLIDEWAY(TM) Access Sheath Portfolio With A New Product For Minimally Invasive Urologic Procedures

周四, 05/15/2014 - 14:25
New GLIDEWAY™ Ureteral Access Sheath Offers Advanced Features Designed to Minimize Trauma SOMERSET, N.J., May 15, 2014 -- (Healthcare Sales & Marketing Network) -- TERUMO, a leading global medical device company, today announced the U.S. launch of its ...
Devices, Interventional, Urology, Product Launch
Terumo Medical, GLIDEWAY, Access Sheath, nephrolithotomy, ureteroscopy

John D. Thompson Joins Transgenomic's Board of Directors

周四, 05/15/2014 - 14:21
OMAHA, Neb.--(Healthcare Sales & Marketing Network)--Transgenomic, Inc. (TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research servi...
Diagnostics, Personalized Medicine, Personnel
Transgenomic, ICE COLD-PCR

Mylan Applauds Court's Ruling Dismissing Teva's Suit Against FDA on Copaxone(R)

周四, 05/15/2014 - 14:18
PITTSBURGH, May 15, 2014 -- (Healthcare Sales & Marketing Network) -- Mylan Inc. (MYL) today commented on the ruling by the U.S. District Court for the District of Columbia against Teva in their suit against the U.S. Food and Drug Administration (FDA), wh...
Biopharmaceuticals, Generics, FDA, Litigation
Mylan, Teva Pharmaceutical, Copaxone

Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer

周三, 05/14/2014 - 12:57
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Agios Pharmaceuticals, Inc. (AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced the appointment of Chris Bowden, M.D., to the newly created po...
Biopharmaceuticals, Personnel
Agios Pharmaceuticals

POZEN Announces U.S. Rights for Treximet(R) to Be Acquired by Pernix Therapeutics

周三, 05/14/2014 - 12:48
POZEN to Receive Pernix Warrants and ROW Rights to Treximet CHAPEL HILL, N.C.--(Healthcare Sales & Marketing Network)--POZEN Inc. (POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that GlaxoSmithK...
Biopharmaceuticals, Acquisitions
POZEN, GlaxoSmithKline, Pernix Therapeutics, Treximet

Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer

周三, 05/14/2014 - 12:42
Company also announces Soon Hyouk Lee as its new Vice President of Business Development ARDSLEY, N.Y.--(Healthcare Sales & Marketing Network)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) has appointed Andrew Hindman as Chief Business Development Officer. ...
Biopharmaceuticals, Personnel
Acorda Therapeutics

Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer

周三, 05/14/2014 - 12:41
Company also announces Soon Hyouk Lee as its new Vice President of Business Development ARDSLEY, N.Y.--(Healthcare Sales & Marketing Network)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) has appointed Andrew Hindman as Chief Business Development Officer. ...
Biopharmaceuticals, Personnel
Acorda Therapeutics

Medrobotics Closes $26 Million Series E Financing

周三, 05/14/2014 - 12:31
Company Prepares for European Commercialization of the Ground-Breaking Flex® System in Otolaryngology RAYNHAM, Mass.--(Healthcare Sales & Marketing Network)--Medrobotics Corp., a surgical products company with core competencies in medical robotics,...
Devices, Surgery, Venture Capital
Medrobotics, Flex System, robotic-assist platform, endoscopic, robotic surgery

Senior Level Changes at Dr. Reddy’s

周三, 05/14/2014 - 12:22
HYDERABAD, India--(Healthcare Sales & Marketing Network)--Dr. Reddy’s Laboratories Ltd. (RDY) today announced that its Board of Directors has decided to have separate roles of the Chairman of the Company and the Managing Director and CEO. It has appoint...
Biopharmaceuticals, Personnel
Dr. Reddy’s Laboratories

Avedro Welcomes Robert J. Palmisano to its Board of Directors

周三, 05/14/2014 - 12:17
Seasoned Veteran in Value Creation for Ophthalmic Medical Device Companies WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that Robert J. Palmisano ...
Devices, Ophthalmology, Personnel
Avedro, KXL System

Gemmus Pharma Closes $3.3M Series B Funding to Develop Superior Flu Drug

周二, 05/13/2014 - 14:55
Company Presenting at 27th Annual International Society for Antiviral Research (ISAR) on Specific Isomer SAN FRANCISCO--(Healthcare Sales & Marketing Network)--Gemmus Pharma Inc. a privately held biotechnology company developing an improved host-targete...
Biopharmaceuticals, Venture Capital
Gemmus Pharma, influenza

Ceterix Orthopaedics Completes $18 Million Financing

周二, 05/13/2014 - 14:52
Company Announces Issuance of Two New U.S. Patents MENLO PARK, Calif.--(Healthcare Sales & Marketing Network)--Ceterix™ Orthopaedics, Inc., a developer of novel surgical tools for arthroscopic procedures, today announced that the company has closed $18 ...
Devices, Orthopaedic, Venture Capital
Ceterix Orthopaedics, arthroscopic

ClearSpec LLC Signs Distribution Agreement with McKesson Medical-Surgical

周二, 05/13/2014 - 14:49
Novel device scientifically proven to improve visualization of the cervix BOCA RATON, Fla.--(Healthcare Sales & Marketing Network)--ClearSpec LLC announced today that it has entered into a distribution agreement with McKesson Medical-Surgical Inc. (“McK...
Devices, Distribution
ClearSpec, McKesson Medical-Surgical, Vaginal Speculum

Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve(R) 100 Novolimus Eluting Coronary Scaffold System

周二, 05/13/2014 - 14:47
Dramatically thinner scaffold combines excellent deliverability and conformability with DESolve’s market-leading clinical benefits SUNNYVALE, Calif.--(Healthcare Sales & Marketing Network)--Elixir Medical Corporation, a developer of product platforms th...
Devices, Interventional Cardiology, Regulatory
Elixir Medical, DESolve 100, Coronary Scaffold, coronary stent

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong